Skip to content
Trial Agents

Universita' Degli Studi Di Perugia

Universita' Degli Studi Di Perugia is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.

4distinct trials
3recorded service labels
1trials with learnings

Data snapshot: 2026-10-09 · About the data

Clinical trial experience

Showing 4 of 4 trials · Latest update first

A single arm, open label, clinical study of cryopreserved autologous CD34+ cells transduced with lentiviral vector containing human ARSA cDNA, for the treatment of early onset Metachromatic Leukodystrophy (MLD)

Sponsor Orchard Therapeutics (Europe) Limited

Start (EU)
Latest update
Estimated end
Not reported
Operational learnings available5 trial-level findings · Read insights
  • The study was authorized and conducted at a single clinical site in Italy, and all treated subjects received OTL-200 in Italy.
  • The planned sample size was based on feasibility in rare MLD rather than statistical considerations.
  • Protocol version 6 expanded eligibility to permit enrollment and treatment of early-juvenile MLD at early symptomatic stages before rapid disease progression.
  • Protocol version 7 specified arrangements for remote follow-up visits, including assessments by local healthcare professionals or teleconferencing.
  • Protocol version 8 reduced required study long-term follow-up to a minimum of 5 years and allowed rollover to a 15-year post-treatment follow-up study.

These findings describe the trial, not the service provider’s performance or responsibility.

Questions about this trial experience

What services are recorded for Universita' Degli Studi Di Perugia?

The 2026-10-09 snapshot links Universita' Degli Studi Di Perugia to 4 distinct CTIS trials. Recorded services include Laboratory services, ARSA activity evaluation in CSF, ARSA-CSF analysis. These are study-specific roles, not a complete or independently verified capability catalogue.

Which therapeutic areas and study phases are recorded for Universita' Degli Studi Di Perugia?

The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Metabolic Disorders, Neurology. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.

In which countries are trials linked to Universita' Degli Studi Di Perugia conducted?

The linked trials record locations in 1 country, including Italy. These are trial locations, not confirmed office locations or countries where Universita' Degli Studi Di Perugia delivered services.

What can this page tell me about Universita' Degli Studi Di Perugia's trial experience?

Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.

About this data & company names

One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.

Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.

Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Universita' Degli Studi Di Perugia. Legacy brands remain separate unless explicitly matched in the name registry.

View recorded company names
  • Universita' Degli Studi Di Perugia

Never miss a new clinical trial insight

We continuously analyze new and updated clinical trial data and publish practical, evidence-led reports for clinical leaders.